Transition from a platform-based to a hybrid business model
First written in FY2023. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AchievedAnnual report
「We are transitioning from our previous platform business to a hybrid business model in which we create our own pipeline while also operating the platform business.」
The company states that the previously planned transition to a hybrid business model took place from 2025, with the in-house pipeline business becoming fully operational alongside the platform business. - 2026-03-02AdvancedGeneral Meetings of Shareholders
「As a step toward transforming into a specialty pharmaceutical company that harnesses AI-driven drug discovery, we will pursue technology development, including more than 9 ongoing joint research projects with academia, while seeking to improve earnings and maximize future value, and will take an aggressive approach.」
Based on a hybrid business model combining the platform business and the in-house pipeline business, the company explicitly stated its aim of transforming into a specialty pharmaceutical company and conducting joint research with academia. - FY2025-H1AdvancedAnnual report
「In parallel, toward future business diversification, we advanced efforts to create new drugs targeting mRNA independently in-house, or to create an in-house pipeline.」
The company advanced the transition from a platform business to a business including its own pipeline and reached the stage of defining the disease target for its first pipeline. - FY2023First statedAnnual report
「We aim to increase the number of partners through the platform business and begin developing our own pipeline once we reach the stage at which sufficient medium- to long-term revenue can be expected from our partners, which we estimate will be around 2026.」
The company plans first to expand its partner base and revenue through the platform business and then, around 2026, transition to a hybrid model involving parallel development of its own pipeline.